Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020

Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE over...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Zou, Macy, Sabaiduc, Suzana, Murti, Michelle, Olsha, Romy, Dickinson, James A, Gubbay, Jonathan B, Croxen, Matthew A, Charest, Hugues, Jassem, Agatha, Krajden, Mel, Bastien, Nathalie, Li, Yan, De Serres, Gaston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043051/
https://www.ncbi.nlm.nih.gov/pubmed/32098644
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.7.2000103
_version_ 1783501390753038336
author Skowronski, Danuta M
Zou, Macy
Sabaiduc, Suzana
Murti, Michelle
Olsha, Romy
Dickinson, James A
Gubbay, Jonathan B
Croxen, Matthew A
Charest, Hugues
Jassem, Agatha
Krajden, Mel
Bastien, Nathalie
Li, Yan
De Serres, Gaston
author_facet Skowronski, Danuta M
Zou, Macy
Sabaiduc, Suzana
Murti, Michelle
Olsha, Romy
Dickinson, James A
Gubbay, Jonathan B
Croxen, Matthew A
Charest, Hugues
Jassem, Agatha
Krajden, Mel
Bastien, Nathalie
Li, Yan
De Serres, Gaston
author_sort Skowronski, Danuta M
collection PubMed
description Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.
format Online
Article
Text
id pubmed-7043051
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-70430512020-03-12 Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020 Skowronski, Danuta M Zou, Macy Sabaiduc, Suzana Murti, Michelle Olsha, Romy Dickinson, James A Gubbay, Jonathan B Croxen, Matthew A Charest, Hugues Jassem, Agatha Krajden, Mel Bastien, Nathalie Li, Yan De Serres, Gaston Euro Surveill Rapid Communication Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage. European Centre for Disease Prevention and Control (ECDC) 2020-02-20 /pmc/articles/PMC7043051/ /pubmed/32098644 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.7.2000103 Text en This article is copyright of the authors or their affiliated institutions, 2020. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Skowronski, Danuta M
Zou, Macy
Sabaiduc, Suzana
Murti, Michelle
Olsha, Romy
Dickinson, James A
Gubbay, Jonathan B
Croxen, Matthew A
Charest, Hugues
Jassem, Agatha
Krajden, Mel
Bastien, Nathalie
Li, Yan
De Serres, Gaston
Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
title Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
title_full Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
title_fullStr Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
title_full_unstemmed Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
title_short Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
title_sort interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza a and b viruses, canada, february 2020
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043051/
https://www.ncbi.nlm.nih.gov/pubmed/32098644
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.7.2000103
work_keys_str_mv AT skowronskidanutam interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT zoumacy interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT sabaiducsuzana interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT murtimichelle interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT olsharomy interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT dickinsonjamesa interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT gubbayjonathanb interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT croxenmatthewa interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT charesthugues interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT jassemagatha interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT krajdenmel interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT bastiennathalie interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT liyan interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020
AT deserresgaston interimestimatesof201920vaccineeffectivenessduringearlyseasoncocirculationofinfluenzaaandbvirusescanadafebruary2020

Ejemplares similares